Ovarian serous borderline tumors with recurrent or extraovarian lesions: a Japanese, retrospective, multi-institutional, population-based study
Authors:
- 1 August 2023
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 28 (10) , 1411-1420
Abstract
Background Ovarian serous borderline tumors (SBT) are typically unilateral and are primarily treated using hysterectomy and bilateral salpingooophorectomy (SO). However, most young patients prefer fertility-sparing surgeries (FSS) with tumorectomy or unilateral SO. Micropapillary morphology and invasive implants have been designated as histopathological risk indicators for recurrence or metastasis, but their clinical impact remains controversial because of limitations like diagnostic inconsistency and incomplete surgical staging. Methods A nationwide multi-institutional population-based retrospective surveillance was conducted with a thorough central pathology review to reveal the clinical features of SBT. Of 313 SBT patients enrolled in the Japanese Society of Clinical Oncology's Surveillance of Gynecologic Rare Tumors, 289 patient records were reviewed for clinical outcomes. The glass slides of patients at stage II–IV or with recurrence or death were re-evaluated by three gynecological pathologists. Result The 10-year overall and progression-free survival (PFS) rates were 98.6% and 92.3%. The median recurrence period was 40 months and 77.0% was observed in the contralateral ovary within 60 months. Patients aged ≤ 35 years underwent FSS more frequently and relapsed more (p < .001). A clinic-pathological analysis revealed diagnosis during pregnancy, FSS, and treatment at non-university institutes as well as advanced stage and large diameter were independent risk factors of recurrence. Among patients having pathologically confirmed SBTs, PFS was not influenced by the presence of micropapillary pattern or invasive implants. Conclusion The recurrence rate was lower in this cohort than previous reports, but the clinical impacts of incomplete resection and misclassification of the tumor were still significant on the treatment of SBT.Keywords
All Related Versions
Funding Information
- Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación (23-A-17)
This publication has 17 references indexed in Scilit:
- Prognosis in Patients With Serous and Mucinous Stage I Borderline Ovarian TumorsInternational Journal of Gynecological Cancer, 2012
- Borderline Tumors of the Ovary: Clinical Course and Prognostic FactorsOnkologie, 2012
- Micropapillary pattern in serous borderline ovarian tumors: Does it matter?Gynecologic Oncology, 2011
- Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovaryAnnals of Oncology, 2009
- Prognostic Factors in Patients with Ovarian Serous Low Malignant Potential (Borderline) Tumors with Peritoneal ImplantsThe Oncologist, 2009
- Clinical outcome and prognostic factors in borderline tumors of the ovary. Results from 17 years' experience in the Kinki District of Japan (1990-2006).2009
- The Recurrence and the Overall Survival Rates of Ovarian Serous Borderline Neoplasms With Noninvasive Implants is Time DependentAmerican Journal of Surgical Pathology, 2006
- Clinical outcome and risk factors for recurrence in borderline ovarian tumoursBritish Journal of Cancer, 2006
- Ovarian Serous Tumors of Low Malignant Potential (Borderline Tumors)American Journal of Surgical Pathology, 2005
- Serous Borderline Tumors of the OvaryAmerican Journal of Surgical Pathology, 2002